Get the Stockscreener App
1.10
14.40%
-0.185
Pre-market:
1.12
0.02
+1.82%
Genprex Inc stock is traded at $1.10, with a volume of 968.15K.
It is down -14.40% in the last 24 hours and up +166.34% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$1.285
Open:
$1.37
24h Volume:
968.15K
Relative Volume:
0.11
Market Cap:
$3.03M
Revenue:
-
Net Income/Loss:
$-31.45M
P/E Ratio:
-1.7742
EPS:
-0.62
Net Cash Flow:
$-24.56M
1W Performance:
-31.25%
1M Performance:
+166.34%
6M Performance:
-54.92%
1Y Performance:
-89.40%
1-Day Range:
$1.095
$1.37
1-Week Range:
$1.095
$1.80
52-Week Range:
$0.2806
$335.84
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| GNPX | 1.10 | 3.03M | 0 | -31.45M | -24.56M | -0.62 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex secures exclusive gene therapy license for cancer - Investing.com India
Genprex secures exclusive gene therapy license for cancer By Investing.com - Investing.com UK
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer - PR Newswire
Genprex faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Genprex faces Nasdaq delisting over equity shortfall - Investing.com
U.S. Stock market top gainers: Mullen Automotive gains 92.92% while Genprex increases by 54.48% during mid day trading - Business Upturn
Genprex reports promising preclinical data on cancer therapy - Investing.com
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - BioSpace
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Thera - GuruFocus.com
Genprex regains Nasdaq compliance with bid price rule - Investing.com India
Genprex regains Nasdaq compliance with bid price rule By Investing.com - Investing.com Australia
Genprex reports promising preclinical data on cancer therapy By Investing.com - Investing.com UK
Genprex Announces Sponsored Research Agreement with The Universi - GuruFocus.com
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Increases By 5.2% - Defense World
Genprex to Participate in 2024 BIO Europe Conference - The Malaysian Reserve
Investor Excitement Sparks Genprex (GNPX) Stock Rally - Stocks Telegraph
Genprex reports positive preclinical gene therapy data By Investing.com - Investing.com South Africa
Genprex reports positive preclinical gene therapy data - Investing.com India
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma - The Malaysian Reserve
Genprex (NASDAQ:GNPX) Announces Sponsored Research Agreement with University of Michigan Rogel Cancer Center for Study on TUSC2 Gene Therapy in ALK-Positive Lung Cancer Patients - Defense World
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.80% - MSN
Genprex explores gene therapy in lung cancer study - Investing.com India
Genprex explores gene therapy in lung cancer study By Investing.com - Investing.com South Africa
Genprex signs two lung cancer research agreements - TipRanks
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive - StreetInsider.com
3 Penny Stocks to Watch Now, 10/24/24 - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.02% - MSN
2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now - Yahoo Finance
Dow Falls Over 150 Points; General Motors Tops Q3 Views - Benzinga
‘Permanent should mean Permanent’: Purbeck calls for commitment to Full Expensing - Yahoo! Voices
TD Bank becomes liquidity provider for LTX - Yahoo! Voices
UK economy 'set to accelerate', says IMF - Yahoo! Voices
IMF's economic view: A brighter outlook for US but still-tepid global growth - Yahoo! Voices
Scotch whisky business Compass Box in overseas push - Yahoo News
Siemens secures contract to optimise Unibuss’ electric fleet with Depot360 - Yahoo! Voices
US dough business Urban Farmer appoints Chris Jaromin as new CEO - Yahoo! Voices
DHL Supply Chain to close Canal Winchester warehouse, lay off more than 150 workers - Yahoo News
QC Copper to acquire remaining 50% of Roger Gold-Copper Project - Yahoo! Voices
CAC introduces cyber cover for energy and utility sectors - Yahoo! Voices
How small Canadian retailers are thriving on multiple sales channels - Yahoo! Voices
Zymeworks doses first subject in Phase I trial of ZW171 for various forms of cancer - Yahoo! Voices
2 Low-Cost Vanguard ETFs for Set-and-Forget Investors - Yahoo! Voices
Eleven unveils AI-driven software tailored for accounting - Yahoo News
Excelsior gets final permit for Arizona copper mine operations - Yahoo News
The Dean Group acquires 280-room Roomer’s Munich hotel - Yahoo! Voices
JCP urges Cheesecake to spin off three brands for growth - Yahoo! Voices
Kmart just closed its last full store — but there’s still a location in Kendall - Yahoo! Voices
These Are the 5 Most Shorted Stocks in the S&P 500 Index. The Bears Are Wrong About 1 of Them. - Yahoo! Voices
This Big Social Security Change Was Just Announced, and It Will Affect Your 2025 Benefits - Yahoo! Voices
HSBC splits up bank amid growing tensions between China and the West - Yahoo! Voices
Regeneron Pharmaceuticals (REGN) Stock Drops Amid Market Volatility - GuruFocus.com
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):